Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
9,144
archived clinical trials in
Ocular

Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
522
mi
from
Austin, TX
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
522
mi
from
Austin, TX
Click here to add this to my saved trials
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
349
mi
from
Dallas, TX
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
349
mi
from
Dallas, TX
Click here to add this to my saved trials
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
346
mi
from
Fort Worth, TX
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
346
mi
from
Fort Worth, TX
Click here to add this to my saved trials
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
779
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
Clinical Research Facility
630
mi
from
Racine, WI
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
Clinical Research Facility
630
mi
from
Racine, WI
Click here to add this to my saved trials
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated:  3/19/2018
1321
mi
from
Edmonton,
Safety & Effectiveness Study of the Hydrus Microstent for Lowering IOP in Glaucoma Patients Undergoing Cataract Surgery (HORIZON)
The Safety and Effectiveness of the Hydrus Aqueous Implant for Lowering Intraocular Pressure in Glaucoma Patients Undergoing Cataract Surgery, A Prospective, Multicenter, Randomized, Controlled Clinical Trial
Status: Enrolling
Updated: 3/19/2018
1321
mi
from
Edmonton,
Click here to add this to my saved trials
PROTECT2: Diabetes Care - Eye Exam
PROTECT2: Diabetes Care - Eye Exam
Status: Enrolling
Updated:  3/21/2018
Dean McGee Eye Institute
158
mi
from
Oklahoma City, OK
PROTECT2: Diabetes Care - Eye Exam
PROTECT2: Diabetes Care - Eye Exam
Status: Enrolling
Updated: 3/21/2018
Dean McGee Eye Institute
158
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
UC Davis Dept of Ophthalmology & Vision Science
1283
mi
from
Sacramento, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
UC Davis Dept of Ophthalmology & Vision Science
1283
mi
from
Sacramento, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Sall Medical Research Center
1164
mi
from
Artesia, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Sall Medical Research Center
1164
mi
from
Artesia, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Scripps Clinic at Torrey Pines
1145
mi
from
La Jolla, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Scripps Clinic at Torrey Pines
1145
mi
from
La Jolla, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Eye Research Foundation
1161
mi
from
Newport Beach, CA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Eye Research Foundation
1161
mi
from
Newport Beach, CA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Coastal Research Associates, LLC
794
mi
from
Atlanta, GA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Coastal Research Associates, LLC
794
mi
from
Atlanta, GA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Clayton Eye Center
808
mi
from
Morrow, GA
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Clayton Eye Center
808
mi
from
Morrow, GA
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Ophthalmology Consultants Ltd
403
mi
from
Saint Louis, MO
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Ophthalmology Consultants Ltd
403
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
UNC Kittner Eye Center
843
mi
from
Chapel Hill, NC
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
UNC Kittner Eye Center
843
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Apex Eye
734
mi
from
Madeira, OH
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Apex Eye
734
mi
from
Madeira, OH
Click here to add this to my saved trials
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated:  3/22/2018
Ophthalmology Associates
348
mi
from
Fort Worth, TX
Bimatoprost Ocular Insert Compared to Topical Timolol Solution in Patients With Glaucoma or Ocular Hypertension
A Phase 2, Multicenter, Randomized, Subject- and Examiner-masked, Controlled Clinical Trial Designed to Evaluate the Safety and Effectiveness of the Bimatoprost Ocular Insert as Compared to Topical Timolol Solution (0.5%) in Patients With Glaucoma or Ocular Hypertension.
Status: Enrolling
Updated: 3/22/2018
Ophthalmology Associates
348
mi
from
Fort Worth, TX
Click here to add this to my saved trials
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Status: Enrolling
Updated:  3/23/2018
Hull Eye Center
1149
mi
from
Lancaster, CA
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery
Status: Enrolling
Updated: 3/23/2018
Hull Eye Center
1149
mi
from
Lancaster, CA
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Coleman Vision
523
mi
from
Albuquerque, NM
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Coleman Vision
523
mi
from
Albuquerque, NM
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Durrie Vision
190
mi
from
Kansas City, MO
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Durrie Vision
190
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
King LASIK
1401
mi
from
Renton, WA
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
King LASIK
1401
mi
from
Renton, WA
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Kraff Eye Institute
610
mi
from
Chicago, IL
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Kraff Eye Institute
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Lehmann Eye Center
458
mi
from
Nacogdoches, TX
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Lehmann Eye Center
458
mi
from
Nacogdoches, TX
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Maloney Vision Institute
1168
mi
from
Los Angeles, CA
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Maloney Vision Institute
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
Pepose Vision Institute
398
mi
from
Chesterfield, MO
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
Pepose Vision Institute
398
mi
from
Chesterfield, MO
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
The Eye Center
1112
mi
from
Fairfax, VA
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
The Eye Center
1112
mi
from
Fairfax, VA
Click here to add this to my saved trials
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated:  3/27/2018
University of Miami, Bascom Palmer Eye Institute
1321
mi
from
Miami, FL
Safety and Effectiveness of Wavefront-Guided LASIK Correction of Hyperopic Refractive Errors
A Prospective Study to Evaluate the Safety and Effectiveness of Wavefront-Guided Lasik Correction of Hyperopic Refractive Errors With the iDesign Advanced Wavescan Studio™ System and Star S4 IR™ Excimer Laser System
Status: Enrolling
Updated: 3/27/2018
University of Miami, Bascom Palmer Eye Institute
1321
mi
from
Miami, FL
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Jules Stein Eye Institute, UCLA
1168
mi
from
Los Angeles, CA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Jules Stein Eye Institute, UCLA
1168
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Denver
404
mi
from
Aurora, CO
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Denver
404
mi
from
Aurora, CO
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Emory University Department of Ophthalmology
803
mi
from
Atlanta, GA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Emory University Department of Ophthalmology
803
mi
from
Atlanta, GA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Iowa Hospitals and Clinics, Department of Ophthalmology
428
mi
from
Iowa City, IA
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Iowa Hospitals and Clinics, Department of Ophthalmology
428
mi
from
Iowa City, IA
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Kellogg Eye Center at University of Michigan
806
mi
from
Ann Arbor, MI
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Kellogg Eye Center at University of Michigan
806
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
University of Nebraska Medical Center, Department of Ophthalmology
259
mi
from
Omaha, NE
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
University of Nebraska Medical Center, Department of Ophthalmology
259
mi
from
Omaha, NE
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Casey Eye Institute, Oregon Health & Science University
1384
mi
from
Portland, OR
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Casey Eye Institute, Oregon Health & Science University
1384
mi
from
Portland, OR
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Hamilton Eye Institute, The University of Tennessee
467
mi
from
Memphis, TN
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Hamilton Eye Institute, The University of Tennessee
467
mi
from
Memphis, TN
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Eye Wellness Center
571
mi
from
Houston, TX
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Eye Wellness Center
571
mi
from
Houston, TX
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Medical College of Wisconsin, The Eye Institute
630
mi
from
Milwaukee, WI
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Medical College of Wisconsin, The Eye Institute
630
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Johannes Gutenberg University Medical Center
554
mi
from
Mainz,
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Johannes Gutenberg University Medical Center
554
mi
from
Mainz,
Click here to add this to my saved trials
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated:  3/27/2018
Washington University Department of Ophthalmology
mi
from
Saint Louis, MO
Teprotumumab (RV 001) Treatment in Patients With Active Thyroid Eye Disease
A Multicenter, Double-Masked, Placebo-Controlled, Efficacy And Safety Study Of RV 001, An Insulin-Like Growth Factor-1 Receptor (IGF-1R) Antagonist Antibody (Fully Human), Administered Every 3 Weeks (q3W) By Intravenous (IV) Infusion In Patients Suffering From Active Thyroid Eye Disease (TED)
Status: Enrolling
Updated: 3/27/2018
Washington University Department of Ophthalmology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study
Status: Enrolling
Updated:  3/28/2018
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Phase 1 Follow-on Study of AAV2-hRPE65v2 Vector in Subjects With Leber Congenital Amaurosis (LCA) 2
A Follow-On Study to Evaluate the Safety of Re-Administration of Adeno-Associated Viral Vector Containing the Gene for Human RPE65 [AAV2-hRPE65v2] to the Contralateral Eye in Subjects With Leber Congenital Amaurosis (LCA) Previously Enrolled in a Phase 1 Study
Status: Enrolling
Updated: 3/28/2018
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study in Subjects With Leber Congenital Amaurosis
A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101]
Status: Enrolling
Updated:  3/28/2018
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Safety Study in Subjects With Leber Congenital Amaurosis
A Phase 1 Safety Study in Subjects With Leber Congenital Amaurosis (LCA) Using Adeno-Associated Viral Vector to Deliver the Gene for Human RPE65 Into the Retinal Pigment Epithelium (RPE) [AAV2-hRPE65v2-101]
Status: Enrolling
Updated: 3/28/2018
Children's Hospital of Philadelphia
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Comparison of Gonioscopy With Cirrus and Visante
Comparison of Visante and Cirrus Optical Coherent Tomography for Assessment of the Anterior Segment
Status: Enrolling
Updated:  3/29/2018
Wills Eye Hospital, Glaucoma Service
1225
mi
from
Philadelphia, PA
Comparison of Gonioscopy With Cirrus and Visante
Comparison of Visante and Cirrus Optical Coherent Tomography for Assessment of the Anterior Segment
Status: Enrolling
Updated: 3/29/2018
Wills Eye Hospital, Glaucoma Service
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Retina Vitreaous Associates
1176
mi
from
Beverly Hills, CA
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Retina Vitreaous Associates
1176
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Retina Macula Institute
1179
mi
from
Torrance, CA
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Retina Macula Institute
1179
mi
from
Torrance, CA
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Retina Consultants of Southern Colorado
386
mi
from
Colorado Springs, CO
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Retina Consultants of Southern Colorado
386
mi
from
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Ophthalmology & Visual Sciences
727
mi
from
Lexington, KY
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Ophthalmology & Visual Sciences
727
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Ocular Immunology and Uveitis Foundation
1441
mi
from
Cambridge, MA
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Ocular Immunology and Uveitis Foundation
1441
mi
from
Cambridge, MA
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Univ of Nebraska Med Ctr
262
mi
from
Omaha, NE
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Univ of Nebraska Med Ctr
262
mi
from
Omaha, NE
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Retina Consultants
1303
mi
from
SLingerlands, NY
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Retina Consultants
1303
mi
from
SLingerlands, NY
Click here to add this to my saved trials
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated:  4/2/2018
Duke University Eye Center
1052
mi
from
Durham, NC
Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert
A Phase III, Multi-National, Multi-Center, Randomized, Masked, Controlled, Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal Insert in Subjects With Chronic Non-Infectious Uveitis Affecting the Posterior Segment of the Eye
Status: Enrolling
Updated: 4/2/2018
Duke University Eye Center
1052
mi
from
Durham, NC
Click here to add this to my saved trials